US Stock MarketDetailed Quotes
ARGX argenx SE
- 596.740
- +4.920+0.83%
Close Nov 21 16:00 ET
- 596.740
- 0.0000.00%
Post 16:00 ET
35.68BMarket Cap-765051P/E (TTM)
601.950High582.070Low417.74KVolume587.390Open591.820Pre Close247.93MTurnover0.70%Turnover RatioLossP/E (Static)59.80MShares611.22352wk High8.37P/B35.67BFloat Cap327.72552wk Low--Dividend TTM59.77MShs Float611.223Historical High--Div YieldTTM3.36%Amplitude17.330Historical Low593.497Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
argenx SE Stock Forum
This approval followed the Adhere study.This concerns an injection of 1,000 milligrams that can be administered once a week. About 50,000 people in China suffer from CIDP.
“It is the first and only treatment approved in China for CIDP,”...
The difference between the operational results and the net result is mainly made up of the financial results and the taxes on the result. At the end of September, Argenx still h...
📌 This week’s PDUFAs:
$Merck & Co (MRK.US)$ : 🤔
⇨ Patritumab deruxtecan
‣ Non-small cell lung carcinoma
‣ PDUFA date: 6/26/24 (BLA)
$Verona Pharma (VRNA.US)$ : 🤔
⇨ Ensifentrine (Nebulized)
‣ Chronic obstructive pulmonary disease
‣ PDUFA date: 6/26/24 (NDA)
$Genmab (GMAB.US)$ : 🤔
⇨ EPKINLY® (Epcoritamab)
‣ Follicular lymphoma
‣ PDUFA date: 6/28/24 (sBLA)
🗓️ Last week’s PDUFAs:
$Merck & Co (MRK.US)$ : Approved 6/17 🎉
⇨ CAPVAXIVE (V116)
‣ Pneumo...
$Harmony Biosciences (HRMY.US)$ : WAKIX (pitolisant)
$Bristol-Myers Squibb (BMY.US)$ : KRAZATI (Adagrasib) + Cetuximab
$argenx SE (ARGX.US)$ : VYVGART Hytrulo (Efgartigimod)
$Merck & Co (MRK.US)$ : Patritumab deruxtecan
$Verona Pharma (VRNA.US)$ : Ensifentrine (Nebulized)
$Rocket Pharmaceuticals (RCKT.US)$ : KRESLADI (Marnetegragene autotemcel)
$GlaxoSmithKline (GSK.US)$ : Arexvy
$Genfit (GNFT.US)$ & $IPSEN SA SPONS ADR EA REPR 0.25 ORD (IPSEY.US)$ : Elafibranor
$Eli Lilly and Co (LLY.US)$ : Donanemab - AdCom meeting 🗓️
$Regeneron Pharmaceuticals (REGN.US)$ : Kevzara (sarilumab)
$Bristol-Myers Squibb (BMY.US)$ : Augtyro™ (Repotrectinib)
$Geron (GERN.US)$ : Imetelstat
$Merck & Co (MRK.US)$ : V116
$Amgen (AMGN.US)$ : BLINCYTO (blinatumomab)
$Sarepta Therapeutics (SRPT.US)$ : ELEVIDYS
$Merck & Co (MRK.US)$ : KEYTRUDA ...
$Bristol-Myers Squibb (BMY.US)$ : Breyanzi
‣ PDUFA date: 5/31/24 (sBLA)
$Moderna (MRNA.US)$ : mRNA-1345
‣ PDUFA date: End of May 2024 (est.) (BLA)
📣 Buckle up & get ready for next month...
June brings 17 PDUFA decisions: 🔥 🔥
$Catalyst Pharmaceuticals (CPRX.US)$ : FIRDAPSE® (Amifampridine)
$GlaxoSmithKline (GSK.US)$ : Arexvy
$Genfit (GNFT.US)$ & $IPSEN SA SPONS ADR EA REPR 0.25 ORD (IPSEY.US)$ : Elafibranor
$Regeneron Pharmaceuticals (REGN.US)$ : Kevzara (sarilumab)
$Bristol-Myers Squibb (BMY.US)$ : Augtyro...
$Mingteng International (MTEN.US)$ buy
no 1. $Biogen (BIIB.US)$ all time low 2 USD
no 2. $Neurocrine Biosciences (NBIX.US)$ all time low 1.9 USD
no 3. $Biohaven (BHVN.US)$ all time low 7 USD
no5. $argenx SE (ARGX.US)$ all time low 17 USD
And it's not bubble. Of course there are also, biotech companies which are failed. But I think if it's growing into a right directio...
$Regenxbio (RGNX.US)$ Phase 2
$Leap Therapeutics (LPTX.US)$ Phase 2
$4D Molecular Therapeutics (FDMT.US)$ Phase 2
$Adverum Biotechnologies (ADVM.US)$ Phase 2
$Denali Therapeutics (DNLI.US)$ Phase 2
$EyePoint Pharmaceuticals (EYPT.US)$ Phase 2
$Xencor (XNCR.US)$ Phase 2
$Harmony Biosciences (HRMY.US)$ Phase 2
$Alnylam Pharmaceuticals (ALNY.US)$ Phase 2
$Disc Medicine (IRON.US)$ Phase 2
$Atea Pharmaceuticals (AVIR.US)$ Phase 2
$Allakos (ALLK.US)$ Phase 2 ...
No comment yet